Get started
Author

Shekeab Jauhari

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
2025 · Alison M. Schram, Koichi Goto, et al. · New England Journal of Medicine · 140
PDF
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
2024 · Dong-Wan Kim, Alison M Schram, et al. · Future Oncology · 43
Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells
2021 · Wei Huang, Yaping Liu, et al. · Frontiers in Immunology · 29
A multi‐institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation
2016 · Sarah A. Milgrom, Shekeab Jauhari, et al. · Cancer · 23
Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).
2022 · Erika P. Hamilton, Shekeab Jauhari, et al. · Journal of Clinical Oncology · 21
A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies
2021 · Manish R. Patel, Varun Monga, et al. · Blood · 20
Abstract P039: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma
2021 · Meredith McKean, Manish R. Patel, et al. · Molecular Cancer Therapeutics · 18
Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.
2021 · Alison M. Schram, Jordi Rodon Ahnert, et al. · Journal of Clinical Oncology · 18
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
2022 · Catherine Thieblemont, Javier Munoz, et al. · Blood · 15
Management of chronic lymphocytic leukemia ( CLL ) in the era of B ‐cell receptor signal transduction inhibitors
2015 · Anthony Mato, Shekeab Jauhari, et al. · American Journal of Hematology · 15
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
2025 · Jean-Pascal Machiels, Jérôme Fayette, et al. · Future Oncology · 14
Microtransplantation in older patients with AML : A pilot study of safety, efficacy and immunologic effects
2020 · Anthony D. Sung, Shekeab Jauhari, et al. · American Journal of Hematology · 13
1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
2023 · A. Schram, K. Goto, et al. · Annals of Oncology · 11
PDF
A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder
2019 · Chester Kao, Megan McNamara, et al. · Clinical Genitourinary Cancer · 7
Living Diabetes: How Disease Perceptions and Cultural Factors Influence Self-Care Behaviors in South Asians in America
2015 · Tasnim F. Imran, Shekeab Jauhari, et al. · Journal of nature and science · 6
Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.
2021 · Nigel Waters, Manish R. Patel, et al. · Journal of Clinical Oncology · 5
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
2024 · Melissa L. Johnson, Beni B. Wolf, et al. · Molecular Cancer Therapeutics · 3
Hepatosplenic T-Cell Lymphoma
2019 · Shekeab Jauhari, Matt McKinney · Springer eBooks · 3
Expression and prognostic relevance of calcium calmodulin-dependent protein kinase kinase 2 (CaMKK2) in chronic lymphocytic leukemia (CLL).
2019 · Shekeab Jauhari, Alicia D. Volkheimer, et al. · Journal of Clinical Oncology · 3
PET/CT in the Evaluation of Relapsed or Refractory Hodgkin Lymphoma.
2016 · Shekeab Jauhari, Sunita D Nasta · PubMed · 3
Consolidative Radiation Therapy Following Autologous Transplantation in Relapsed or Refractory Hodgkin Lymphoma
2015 · Shekeab Jauhari, John Plastaras, et al. · Blood · 3
Comparison of Clinical Outcomes in Early Stage Triple Negative Breast Cancer Treated With Mastectomy Versus Breast Conserving Therapy
2012 · B. Ly, D. Kwon, et al. · International Journal of Radiation Oncology*Biology*Physics · 3
595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
2023 · D-W. Kim, K. Goto, et al. · Annals of Oncology · 2
PDF
Safety, tolerability, and preliminary efficacy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in combination with pembrolizumab in subjects with solid tumors.
2022 · Shekeab Jauhari, Antonio Jimeno, et al. · Journal of Clinical Oncology · 2
Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.
2021 · Raghad Muhsin Abdul-Karim, Anthony W. Tolcher, et al. · Journal of Clinical Oncology · 2
Works count: 58
Citation count: 424
H-index: 12
I10-index: 13
Year
Topic
Type